Dupilumab-Associated Sezary Syndrome

Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of dermatology Vol. 68; no. 4; pp. 459 - 462
Main Authors Hamp, Austin, Hanson, Jamie, Alhatem, Albert, Schwartz, Robert A
Format Report
LanguageEnglish
Published 01.07.2023
Online AccessGet full text

Cover

More Information
Summary:Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon.
Bibliography:ObjectType-Case Study-2
content type line 59
SourceType-Reports-1
ObjectType-Report-1
ISSN:1998-3611
DOI:10.4103/ijd.ijd_580_22